Investing in Private Cannabis Debt Funds: Yields, Risks, and Opportunities for Accredited Investors

Private cannabis debt has quietly become one of the most compelling niches in alternative credit. For accredited investors seeking double-digit yields backed by hard assets, it deserves serious consideration - and serious scrutiny.

Executive summary: why accredited investors are looking at cannabis private debt now

The regulated U.S. cannabis market generated roughly $30–32 billion in legal sales in the 2024–2025 period, with projections suggesting the cannabis market could approach $46 billion by 2028. Yet despite this scale, most cannabis operators remain structurally underbanked. Federal illegality under the Controlled Substances Act - even after partial rescheduling in April 2026 - keeps national banks on the sidelines, creating a persistent capital gap that private lenders can fill at premium rates.

This is the core thesis: structurally limited bank capital, compounded by Section 280E tax friction and state licensing caps, has created an enduring niche for senior secured cannabis lending. Flagship managers like Chicago Atlantic BDC report portfolio-level gross yields near 15.8%, well above the 7–11% typical of traditional middle-market private credit. Net investor IRRs in well-diversified cannabis debt funds generally land in the 10–13% range - attractive risk adjusted returns for a credit strategy backed by real estate, equipment, and license collateral.

For 506 Investor Group members, this opportunity carries an additional advantage. The group's collective bargaining power - over 4,000 members with more than $1.5 billion invested historically on negotiated terms - has translated into improved economics on several cannabis credit allocations, including lower management fees and enhanced investor protections.

This article covers:

• Return profiles, structures, and cash flow patterns for cannabis private debt
• Risk factors including regulatory uncertainty, cannabis use disorder, and cannabis smoke–related reputational issues
• Manager landscape: Chicago Atlantic BDC, Pelorus, and other key players
• Case studies of real-deal structures
• A due diligence checklist tailored for sophisticated accredited investors

Regulated cannabis industry backdrop: market size, structure, and capital gaps

Cannabis is a genus of flowering plants in the family Cannabaceae. It is classified into three main types: Sativa, Indica, and Hybrid. Sativa strains are known for being uplifting and energetic, while Indica strains are known for being relaxing and sedative. The cannabis plant contains over 100 compounds called cannabinoids, primarily THC and CBD, where THC is the psychoactive compound that causes the "high" and CBD generally provides non-intoxicating, calming effects.

For investors, what matters is how this plant has spawned a multi-billion-dollar regulated industry. Whitney Economics forecasts U.S. legal cannabis sales topped $31.4 billion in 2024, growing at roughly 6–9% annually. In 2022, cannabis was the world's most widely produced drug, and as of that year, 24 U.S. states had legalized recreational cannabis use. Canada legalized recreational cannabis on October 17, 2018. Uruguay legalized cannabis in December 2013, making it the first country to do so nationally. The U.S. cannabis market is projected to grow significantly by 2026 and beyond.

Cannabis products are available in various forms including flower, concentrates, edibles (including baked goods and beverages), and tinctures. Cannabinoids can be extracted to create tinctures using high-proof spirits. Cannabis can be consumed by smoking, vaping, or edibles. Dried flower buds contain 3% to 20% THC, while cannabis oil may contain more than 60% THC. Hashish can be consumed orally or smoked. Marijuana is cannabis with higher THC levels, generally over 0.3%, while hemp is cannabis containing 0.3% or less THC, used for fiber and oils. Cannabis products sold in dispensaries may vary in potency and composition.

Cannabis is used recreationally for relaxation and euphoria. The average THC level in U.S. cannabis rose dramatically since the 1970s, reflecting consumer demand for higher-potency products. These product segments - from flower to concentrates to medical formulations - affect collateral values and working-capital needs for borrowers in different ways.

State-level licensing regimes limit the number of licenses for cultivation, processing, and retail, creating local oligopolies that increase barriers to entry. These same structures intensify capital needs for real estate, equipment, and inventory. Yet most state licensed cannabis operators remain structurally underbanked: federal illegality prevents national banks from offering full services, payment processing is constrained, and insurance remains difficult to obtain.

Section 280E of the Internal Revenue Code prevents cannabis businesses from deducting ordinary expenses - rent, payroll, utilities - driving effective tax rates to 60–70% or higher. This tax drag compresses free cash flow and raises credit risk, but it also creates the very funding gap that private cannabis debt funds seek to monetize. Sometimes affectionately called mary jane in popular culture, this plant has become the basis for an asset class that demands serious financial analysis.

Why debt, not equity: comparing cannabis credit to cannabis equity investments

Public cannabis equities experienced a devastating boom-bust cycle between 2018 and 2021. SPACs, Canadian LPs, and U.S. multi-state operators surged on legalization optimism, then cratered - many losing 70–90% of their peak valuations. Market cycles in cannabis equities have been driven more by political sentiment than fundamentals.

Senior secured private debt has told a different story. While equity investors depended on growth narratives and multiple expansion, lenders collected contractual cash flows - coupons, origination fees, and exit fees - backed by recourse to hard assets. Chicago Atlantic BDC's portfolio, for example, shows non-accruals of approximately 2.2% at cost, a far cry from equity wipeouts in the same period.

The capital-stack positioning matters. In downside scenarios, real estate and equipment collateral in cultivation and processing facilities has enabled partial or full recovery for senior secured lenders even when equity was entirely wiped out. Section 280E amplifies this dynamic: high effective tax rates crush equity free cash flow, but lenders underwrite to asset values and EBITDA with cash sweeps and tight covenants, building in margin of safety.

The illiquidity tradeoff is real. Private credit typically offers quarterly or annual liquidity with gates, while public equity is liquid but volatile. Many investors exploring alternative investments use cannabis debt as a yield sleeve rather than a trading vehicle - a stable cash-flow generator within a broader portfolio.

Equity makes sense for high-risk growth bets on cannabis industry consolidation. Debt is the better fit for income-oriented accredited investors seeking capital preservation with double-digit current yield.

How private cannabis debt funds are structured

Cannabis private debt reaches investors through several vehicle types, each with distinct implications:

• Private credit funds (LP/GP structure): typically Reg D offerings, K-1 reporting, 2–5 year lockups, and significant minimum investments
• Business Development Companies (BDCs): like Chicago Atlantic BDC - publicly traded, 1099 reporting, daily liquidity but mark-to-market volatility
• Mortgage REITs: focused on cannabis real estate debt, offering REIT tax treatment and dividend pass-through
• Interval funds: periodic liquidity windows (typically quarterly), accessible to accredited investors with lower minimums

Core loan types include senior secured real estate mortgages, equipment financing, construction loans, working-capital lines, and hybrid facilities. Many are cross-collateralized by cannabis licenses and personal guarantees from principals.

Common deal terms in the current environment:

• Cash coupons: 10–15%, often with PIK components of 1–3%
• Origination fees: 1–3% upfront
• Exit fees: 1–2.5x in some structures
• Prepayment penalties: common in first 12–24 months
• Equity kickers: warrants or profit participation in select deals

Loan tenors generally run 2–5 years for working capital and equipment, stretching to 5–12 years for real estate. LTV ratios typically target 60–65% for real estate, with tighter advance rates on equipment and inventory. Covenant packages include minimum cash balances, debt service coverage ratios, monthly reporting, change-of-control clauses, and regulatory compliance requirements.

Funds manage concentration risk through exposure limits by borrower, state, and subsector. A well-run portfolio might cap any single borrower at 3–5% and any single state at 20–25%. Cannabis-specific adaptations - such as specialized regulatory counsel and license-value monitoring - distinguish these structures from traditional middle-market credit funds.

Return expectations: yields, total return profile, and cash flow patterns

Realistic return expectations for accredited investors in diversified senior secured cannabis funds:

• Gross portfolio yields: mid-teens (Chicago Atlantic BDC reported 15.8% weighted average yield as of Q1 2026)
• Net investor IRRs: 10–13% after fees, defaults, and fund expenses
• Upside scenarios: mid-teens net when leverage, equity kickers, and favorable regulatory tailwinds align

Return components break down into running coupon income (the primary driver), upfront origination and backend exit fees, OID accretion, default recoveries, and any equity participation. Chicago Atlantic BDC's Q1 2026 results illustrate a portfolio of $364 million at fair value, with approximately 76% in floating-rate loans, nearly all with rate floors.

Cash flow patterns vary depending on fund structure. BDCs and REITs typically distribute dividends quarterly. Private funds may distribute interest monthly or quarterly, with principal returning through amortization or bullet payments at maturity. Reinvestment periods allow managers to recycle capital into new loans as existing facilities pay down.

Compared to mainstream private debt strategies - where direct lending to non-cannabis middle-market borrowers yields 7–11% gross - cannabis debt offers a 400–800 basis point spread premium. This compensates for regulatory complexity, collateral enforceability challenges, and the sector's idiosyncratic risk profile.

Several factors may compress or expand yields over time: regulatory milestones like full rescheduling, banking reform legislation, shifting risk perception around cannabis use, and capital flows from institutional investors entering the space. As more capital enters, spreads in mature states will likely tighten, while newly legal or complex jurisdictions continue offering wider premiums.

The 506 Investor Group's collective scale has helped members negotiate lower management fees and access preferred share classes in several cannabis credit opportunities - improvements that directly enhance net returns.

Risk landscape specific to cannabis debt vs traditional private credit

Cannabis debt carries every risk present in traditional private credit, plus several that are entirely unique to the sector. Investors should categorize these systematically.

Regulatory and federal illegality risk. Although medical cannabis was rescheduled to Schedule III in April 2026, recreational marijuana and most commercial operations remain Schedule I. Full rescheduling hearings began June 29, 2026, but outcomes remain uncertain. A shift in federal enforcement posture could disrupt state-legal operations overnight.

Tax risk (280E). Section 280E remains in force for all cannabis that stays on Schedule I. This structural tax drag can make otherwise profitable operators look cash-starved. Lenders who fail to model EBITDA after the 280E adjustment risk overvaluing borrower cash flows.

Collateral enforceability risk. Cannabis licenses are typically non-transferable without state regulatory approval. Change-of-control provisions, zoning rules, and environmental codes can delay or impair a lender's ability to realize collateral value in default. The interplay between federal and state law adds further complexity to foreclosure and receivership.

Operator-level risk. Weak management, poor compliance records, inadequate internal controls around inventory and cash handling, or exposure to product recalls - including health scares like cannabinoid hyperemesis syndrome - can lead to adverse outcomes for lenders. The cannabis industry remains young, and many operators lack the governance infrastructure investors expect in traditional middle-market borrowers.

Reputational and ESG risk. Some institutional allocators still classify cannabis alongside drug use and "sin" sectors. Concerns about cannabis use disorder, secondhand cannabis smoke, and public health outcomes can constrain LP capital flows and insurance availability, indirectly affecting collateral valuations.

Historical loss experience. Chicago Atlantic's non-accrual rate of approximately 2.2% at cost suggests well-underwritten portfolios can manage defaults, but this data set is limited. Cannabis prices in Colorado dropped 40% from 2014 to 2019, illustrating the kind of price compression that can stress even well-collateralized loans.

For most accredited investors, cannabis debt belongs as a satellite position - perhaps 3–10% of a broader private credit allocation - rather than a core holding.

Regulatory and tax environment: 280E, rescheduling, and banking access

Understanding the legal status of cannabis at the federal level is essential for evaluating credit risk. Cannabis laws vary widely by country and state. In the U.S., cannabis has been classified as Schedule I under the Controlled Substances Act since 1970. The Netherlands decriminalized cannabis in the 1970s. Malta legalized recreational cannabis in 2021. Germany legalized recreational cannabis in April 2024.

On April 23, 2026, the Department of Justice issued a final order rescheduling certain medical cannabis products - specifically FDA-approved drugs and products under state-issued licenses for medical use - from Schedule I to Schedule III. Recreational cannabis remains Schedule I.

Section 280E disallows all deductions except cost of goods sold for businesses trafficking in Schedule I or II substances. This drives effective tax rates to 60–70% or more for many cannabis operators, particularly those with high overhead relative to COGS. Cannabis is legal for medical use in many U.S. states, and medical marijuana programs have expanded significantly over the past decade, but the 280E burden remains severe for operators in both medical and recreational cannabis markets.

Potential rescheduling or descheduling of all cannabis could eliminate 280E, dramatically improving after-tax cash flows and re-rating the sector from a credit perspective. However, this also carries a downside: as banking access opens, traditional lenders may enter, compressing spreads and reducing the opportunity for specialized private credit funds.

Banking reform has been incremental. State-chartered banks and credit unions serve many cannabis operators, but major national banks remain cautious. Payment processing, insurance, and financial services remain constrained for most operators in the cannabis industry.

Individual states' regulatory regimes - licensing caps, vertical-integration mandates, social-equity rules - materially affect collateral values and the attractiveness of specific markets from a lender's perspective. Medical cannabis dispensaries in tightly licensed states tend to have more defensible market positions than operators in states with unlimited licensing. Cannabis is used to treat chronic pain and muscle spasms, and evidence supports cannabis use for neuropathic pain treatment, driving demand through medical purposes channels.

Investors should question any cannabis debt fund manager closely about their in-house regulatory counsel, policy monitoring processes, and ability to react to state-level changes that could affect portfolio companies.

Understanding operator fundamentals: how lenders underwrite cannabis businesses

Underwriting cannabis operators requires deep expertise beyond traditional credit analysis. Key pillars include:

• License quality and durability: Is the license in a limited-license state? How long until renewal? What are the change-of-control provisions?
• Location and zoning: Proximity to population centers, compliance with local odor and ventilation regulations, and whether the property has alternative-use value
• Operational efficiency: Yield per square foot, cost per gram, labor productivity, and compliance track record
• Revenue composition: Split between medical and adult-use, wholesale versus retail, and across product categories - flower, vapes, edibles, concentrates

Lenders analyze margin stability by stress-testing revenue against price compression scenarios. Cannabis operators in states that have recently added adult-use programs often see initial revenue surges followed by pricing pressure as supply increases. Financial metrics include same-store sales trends, cash conversion cycles, and debt service coverage ratios under multiple scenarios.

Compliance and risk management are critical underwriting inputs. Operators must demonstrate sound practices around inventory tracking (seed-to-sale), cash handling (given limited banking access), packaging regulations, and product safety. Consultation with a healthcare provider is necessary before integrating cannabis into a medical routine, and operators in the medical segment must ensure their marketing and dispensary practices reflect this standard.

Physical collateral inspections - site visits to cultivation facilities, processing labs, and retail locations - are non-negotiable. Lenders must verify that assets are not overvalued relative to non-cannabis real estate benchmarks, since conversion costs and regulatory restrictions can significantly discount a property's alternative-use value.

Sponsor backing and corporate governance matter especially when private equity firms or family offices own controlling stakes. Lenders evaluate governance structures, board composition, and whether sponsors have demonstrated willingness to inject additional equity during stress periods.

Questions 506 Investor Group members should pose to fund managers:

• What is your average underwriting timeline per deal?
• How many loans have required covenant waivers or amendments?
• What is your workout team's experience, and have they taken back a cannabis asset?
• How do you model 280E impact on borrower cash flows?

Collateral, structuring, and enforcement in cannabis lending

The typical collateral stack backing cannabis loans includes:

• State-issued cultivation, processing, or retail licenses
• Land, buildings, and leasehold improvements
• Greenhouses, indoor grow facilities, and extraction equipment
• Inventory and receivables
• IP, trademarks, and brand value (in select deals)
• Personal guarantees from principals

License collateral is both the most valuable and most complex component. Licenses are subject to state restrictions on transfer, require regulatory approval for any change of control, and often involve special receivership processes that differ from conventional commercial foreclosure. A lender cannot simply seize a license and sell it on the open market.

Common structural protections include:

• First-lien positions on all assets
• Cross-default provisions linking multiple facilities
• Cash dominion and lockbox structures prioritizing debt service
• Springing recourse that converts non-recourse to full recourse upon trigger events
• Change-of-control clauses requiring lender consent for ownership transfers

Enforcement in default presents practical challenges. State regulators must typically approve any transfer of cannabis assets, and the process can take months. The interplay between federal and state law adds uncertainty - particularly for recreational operations that remain Schedule I. Recovery ranges vary depending on state, asset type, and market conditions. Real estate collateral in strong markets may recover 70–90 cents on the dollar; license value recovery is harder to predict.

Compared to traditional asset-based lending, cannabis enforcement is slower, more regulated, and more uncertain. This complexity is precisely what justifies the higher interest rates and tighter structures that cannabis borrowers accept.

Investor checklist for collateral assessment:

• Does the fund require first-lien positions on all loans?
• How does the manager value license collateral?
• What is the fund's historical recovery rate on defaulted loans?
• Does the fund have relationships with state regulators to facilitate workouts?

Health, social, and ESG considerations: reputational risk and policy overhang

Cannabis occupies a unique position in the investment landscape because of ongoing public-health debates. Investors in cannabis debt need to understand these issues - not because they're making clinical judgments, but because health research shapes regulation, regulation shapes operator margins, and margins determine credit quality.

Cannabis is not recommended as a first-line treatment for common mental health conditions. However, it has demonstrated therapeutic value in specific areas: cannabidiol (CBD) is effective in reducing seizure frequency in epilepsy, cannabis can reduce chemotherapy-induced nausea and vomiting in patients with serious illness, and cannabis may improve appetite in HIV/AIDS patients through increased appetite effects. These medical applications underpin a substantial portion of the cannabis industry's revenue base.

On the risk side, cannabis use disorder can develop in about 9% of users. Cannabis can increase heart rate and blood pressure after consumption, and cannabis users have a 29% higher risk of heart attack and a 20% higher risk of stroke, contributing to concerns about cardiovascular disease and heart disease. Research shows cannabis can impair memory, attention, and executive function, particularly affecting working memory. Long-term, early-onset cannabis use is linked to permanent IQ loss, representing earlier onset of cognitive decline. Cannabis users are three to seven times more likely to cause vehicle crashes. Cannabis use disorder increases mortality rates nearly threefold.

Research suggests cannabis may worsen depression in some individuals, and it can cause acute psychosis lasting up to six hours, particularly at high doses. Heavy cannabis use over long periods raises additional concerns. Cannabis withdrawal can produce the following symptoms: irritability, insomnia, decreased appetite, and anxiety - collectively termed cannabis withdrawal symptoms. The national institute of drug abuse has documented these patterns extensively.

Consuming cannabis through smoking produces cannabis smoke that shares some characteristics with tobacco smoke, including particulate matter that can contribute to chronic bronchitis. Secondhand cannabis smoke exposure has become a regulatory focus, prompting ventilation requirements and smoke-free zone policies for cannabis operators. Other side effects reported in clinical literature include abdominal pain (particularly associated with cannabinoid hyperemesis syndrome), anxiety, and psychoactive effects that vary depending on dose and individual tolerance.

Synthetic cannabinoids - compounds that are chemically similar to natural cannabinoids but frequently found in unregulated products - represent a separate drug abuse concern that occasionally spills into regulatory discussions about the legal cannabis market. These substances, sometimes used alongside other drugs or other substances including alcohol, have been linked to severe negative effects and adverse outcomes that are distinct from regulated cannabis products. Smoking cannabis remains the most common consumption method, though non-combustible alternatives are gaining market share.

The health effects of cannabis extend to interactions with other medicines, and cannabis should not be used as a substitute for prescribed treatments without medical supervision. A meta analysis of available evidence supports therapeutic use in narrow indications while flagging risks for broader populations, especially those with predisposition to mental health conditions or drug use histories.

From a credit investor's perspective, these health debates shape regulation. Tighter dosage limits, packaging requirements, and advertising restrictions increase compliance costs for operators, potentially compressing margins that support debt service.

Some institutional investors still classify cannabis alongside other "sin" sectors, keeping large pools of capital on the sidelines. This reputational sensitivity - while creating challenges for capital formation - also contributes to persistently higher spreads for investors comfortable with the sector. Common side effects and policy concerns around heavy cannabis use and its connection to mental health outcomes influence legislative direction and, indirectly, credit conditions.

For 506 Investor Group members, the advice is straightforward: decide in advance where your ethical boundaries lie and ensure that any cannabis debt fund's ESG framework is transparent. Medical purposes lending carries different reputational weight than financing recreational dispensaries in markets with limited regulatory maturity.

Key private credit players and fund types in the cannabis space

The cannabis credit landscape includes several distinct categories of lenders:

Dedicated cannabis private credit funds - purpose-built vehicles with teams focused exclusively on cannabis lending, offering deep expertise in state-level licensing, operator underwriting, and regulatory navigation.

Cannabis-focused mortgage REITs - Pelorus Equity Group operates a REIT specializing in value-add senior secured real estate debt for cannabis properties. Pelorus completed a $50 million CMBS securitization of cannabis-linked mortgages, with the offering yielding approximately 11% and achieving an "A" rating from Egan-Jones. This securitization milestone signals growing institutional acceptance of cannabis collateral.

BDCs with material cannabis exposure - Chicago Atlantic BDC (ticker: LIEN) is the most prominent publicly traded vehicle, reporting a $364 million fair-value portfolio as of March 2026 with all debt investments in senior secured positions. Its weighted average yield of 15.8% significantly exceeds non-cannabis peer averages of approximately 10.8%.

Hybrid real estate/debt platforms - Alta Real Estate Fund I focuses on senior secured financing through sale-leaseback structures, having invested over $70 million across 31 portfolio properties. Assets are marked to repurposable or non-cannabis uses to protect downside.

Key differences between public and private vehicles:

• Public BDCs/REITs: daily liquidity, mark-to-market volatility, greater disclosure, lower minimums
• Private funds: less liquidity but stronger structural protections, potential for negotiated side letters, alignment with long-term private debt strategies

Some generalist private credit managers have quietly allocated capital into the cannabis market through bespoke structures, while others remain restricted by compliance mandates. The 506 Investor Group does not accept self-promotion or capital raisers, but members regularly surface these managers' offerings for unbiased discussion and collective due diligence.

When evaluating managers, prioritize AUM stability, track record through market cycles, realized loss history, and team continuity over headline yield claims.

Case study: senior secured real estate lending to cannabis operators

Consider the structure of the Chicago Atlantic Real Estate Finance (REFI) - Koach Capital transaction, which illustrates how cannabis real estate credit is priced and structured.

Deal parameters:

• $62.5 million of second-lien notes
• Secured by 32 cannabis retail properties
• 12% total coupon (10% cash interest, 2% PIK)
• 2.5x exit fee if repaid early
• Senior debt of approximately $39 million in first-lien position ahead of the notes
• Weighted average maturity of approximately 12 years

This deal sits behind the first-lien holders in the capital stack. If the borrower defaults, the $39 million of senior debt gets repaid first; the Koach notes absorb loss only after that senior tranche is made whole. The 12% coupon and 2.5x exit fee compensate for this subordination risk and the long duration.

Underwriting considerations: The 32 retail properties provide geographic diversification across multiple state licensing regimes. Each property's value as a cannabis retail location depends on the license attached to it - without an active license, the real estate may be worth substantially less. The lender would have evaluated tenant cash flows, state regulatory stability, lease structures, and each property's alternative-use value.

Performance and risk factors: Cannabis prices in Colorado dropped 40% from 2014 to 2019, showing the kind of price compression that can stress retail operators. For a deal with 12-year weighted average maturity, the lender must assume multiple market cycles will occur during the loan's life. Covenant packages would include minimum revenue thresholds, regulatory compliance requirements, and change-of-control protections.

Lessons for investors:

• Second-lien positions carry meaningful subordination risk, especially with long duration
• Exit fees and PIK components defer cash returns, increasing reinvestment and credit risk
• Geographic diversification across properties helps, but license-value risk concentrates in individual state regimes
• Long-dated deals require confidence in the operator's ability to navigate regulatory evolution over a decade-plus horizon

Case study: working-capital and equipment financing for a multi-state operator

The AFC Gamma - Story of Maryland transaction provides a contrasting example of shorter-duration cannabis lending.

Deal parameters:

• $41 million senior secured credit facility
• Borrower: Story of Maryland, a vertically integrated cannabis operator
• Purpose: refinance existing debt and provide working capital
• Collateral: real property, cannabis licenses, and operational assets
• Structure: term loan with first-lien security interest

Facility structure: The credit facility likely included a term component for fixed assets and a revolving or availability-based component for inventory and receivables. In typical cannabis working-capital facilities, blended interest rates range from 13–15%, with availability formulas tied to eligible receivables and inventory advance rates that are more conservative than in non-cannabis industries.

Collateral and monitoring: The all-assets lien gave the lender recourse to real property, equipment, inventory, and the value of cannabis licenses. Borrowing base certificates - submitted monthly - allowed the lender to monitor collateral coverage. The vertically integrated structure (cultivation, processing, and retail) meant the lender needed to evaluate performance across the entire supply chain.

Challenges and resolution: Working-capital facilities in the cannabis industry face distinct risks: price compression in wholesale markets, delayed market openings in new states, and regulatory shifts affecting same-store sales. When these pressures hit covenant levels, lenders typically respond with waivers, covenant resets, or requirements for additional equity injection from sponsors.

Key protections that proved valuable:

• Cash dominion structures that captured operating cash flow before distribution to equity holders
• Tight EBITDA definitions that excluded one-time regulatory costs and tax adjustments
• Intercreditor arrangements governing relationships with other lenders in the capital structure

Comparison to traditional mid-market equipment lending: In a non-cannabis industry, a similar-sized equipment and working-capital facility might carry a 7–10% interest rate, with more standardized UCC foreclosure procedures and no license-value complexity. The 300–600 basis point premium in cannabis compensates for regulatory uncertainty, collateral enforceability challenges, and the lack of mainstream banking alternatives. The underlying credit analysis - cash flow coverage, asset values, sponsor support - remains fundamentally similar.

Comparing cannabis debt to other alternative income strategies

For investors already allocated to private credit through 506 Investor Group deal flow, cannabis debt occupies a specific niche in the return spectrum.

Yield comparison:

• Traditional direct lending (non-cannabis middle market): 7–11% gross
• Real estate debt funds: 8–12% gross
• Cannabis senior secured debt: 12–18% gross
• Mezzanine/second-lien credit: 12–16% gross

Cannabis senior secured debt offers yields comparable to mezzanine credit in traditional markets, but with first-lien positioning. This is the fundamental anomaly that attracts capital.

Correlation characteristics: Cannabis credit performance has limited correlation with general economic market cycles and interest-rate moves. Demand for cannabis products is relatively inelastic - more akin to alcohol and tobacco than to discretionary consumer goods. However, regulatory events can create idiosyncratic volatility unrelated to broader markets.

Duration and reinvestment risk: Shorter tenors (2–5 years) and floating-rate structures in cannabis loans provide natural protection against rising rates - a structural advantage over longer-dated fixed-rate exposures common in other private credit strategies.

Tax considerations: Interest income from cannabis debt funds is taxed as ordinary income. Fund structure matters: REIT dividends receive pass-through treatment, while partnership K-1s may include complex items. Potential UBTI in tax-exempt accounts should be evaluated for partnership-structured funds.

Portfolio positioning: Cannabis debt works best as a targeted satellite exposure - perhaps 5–10% of a private credit allocation - that provides diversification by sector, borrower profile, and regulatory regime. It should complement, not replace, core positions in traditional direct lending or real estate debt. The ESG profile requires independent consideration, as cannabis remains sensitive for some investors even as markets internationally - from Latin America to developing Europe to the Middle East - continue evolving their regulatory frameworks around cannabis. These emerging markets for cannabis legalization may eventually create additional lending opportunities outside the U.S.

Due diligence checklist for cannabis private debt funds

A structured approach to evaluating cannabis debt opportunities, tailored for sophisticated accredited investors:

Manager evaluation

• Years of experience in cannabis-specific credit (not just general private lending)
• Track record through at least one full regulatory or pricing cycle
• Team stability - has the investment team remained intact?
• Personal capital invested alongside LPs (skin in the game)
• Realized loss history, including detailed attribution of any defaults

Strategy assessment

• Target sectors: cultivation, processing, retail, or diversified?
• State concentration - is the portfolio exposed to a single regulatory regime?
• Average LTV on real estate deals and advance rates on working capital
• Use of fund-level leverage and its impact on returns and risk
• Concentration limits by borrower (target <5%) and state (target <25%)

Risk and compliance

• Legal opinions on enforceability of license collateral in each state
• Process for monitoring regulatory changes across all portfolio states
• KYC/AML policies and procedures for preventing diversion to illicit markets
• Insurance coverage for portfolio companies and the fund itself

Operational due diligence

• Fund administrator quality and independence
• Valuation methodology for loans and license collateral
• Audit firm reputation and cannabis-sector experience
• Reporting frequency, detail, and transparency
• Stress-testing practices across pricing, regulatory, and tax scenarios

Investor alignment

• Management fee (target 1–1.5%) and performance fee (target 15–20% over preferred return)
• Preferred return hurdle, catch-up mechanics, and clawback provisions
• Related-party transactions that could create conflicts of interest
• Side-letter provisions available for larger commitments or group allocations

506 Investor Group members should share sponsor materials and due-diligence findings within the group (without self-promotion) to benefit from peer review and collective negotiation leverage.

Assessing risk–reward: where cannabis debt belongs in a sophisticated portfolio

Sizing a cannabis debt allocation requires honest scenario analysis:

Base case (60% probability): Double-digit net yields with modest defaults (2–4% non-accrual rate). Regulatory progress continues incrementally. Net IRR: 10–13%.

Downside case (25% probability): Elevated defaults from price compression or regulatory setbacks, slower recoveries due to collateral enforceability friction, potential fund extensions. Net IRR: 5–8%.

Upside case (15% probability): Full rescheduling eliminates 280E, banking access normalizes, collateral values appreciate. Near-term yields remain high before spread compression. Net IRR: 14–18%.

For most accredited investors, a 5–10 year view is appropriate. The cannabis industry's capital markets will mature over this period, and closed-end fund lives of 5–7 years align with this trajectory. Building diversification within cannabis exposure - across multiple managers, strategies, and states - is critical.

Monitoring signals to watch annually:

• Federal rescheduling progress and DOJ enforcement posture
• State-level pricing trends and competitive dynamics
• Fund-level non-accrual rates and covenant compliance metrics
• Changes in banking access or institutional capital flows into the sector

Behavioral pitfalls to avoid:

• Chasing the highest stated yield without understanding subordination and structure
• Underestimating legal complexity and enforcement timelines
• Assuming cannabis will inevitably follow alcohol's post-Prohibition trajectory (it may, but on a different timeline and with different regulatory architecture)

Cannabis debt offers a compelling risk-adjusted return as of 2026, but only for investors who approach it with the analytical rigor it demands.

The 506 Investor Group perspective: collective due diligence and negotiated terms

The 506 Investor Group operates as a community of sophisticated accredited passive investors sharing alternative investment ideas - including cannabis credit - with no sponsors or capital raisers allowed. This structure eliminates the conflicts of interest that often distort information in specialized sectors like cannabis, where optimism bias and information asymmetry run particularly high.

Unbiased deal flow comes exclusively from members, not from managers pitching product. When a cannabis debt opportunity surfaces, it receives scrutiny from investors with diverse professional backgrounds - real estate, law, tax, operations - who collectively identify risks that individual investors might miss.

The group's scale translates directly into improved economics. With over 4,000 members and more than $1.5 billion invested historically with special terms negotiated on behalf of members, the 506 Investor Group has secured lower management fees, reduced performance fees, enhanced reporting requirements, and stronger side letters on several private credit deals - including cannabis-focused offerings.

In a sector where fund terms can vary significantly and where information quality from managers is uneven, this collective approach provides a meaningful edge. Members have identified problematic fee structures, weak collateral packages, and insufficiently experienced management teams through shared due diligence that no single investor could replicate alone.

Each member remains fully responsible for independent investment decisions consistent with their risk profile and objectives. This article is a starting point for education - not a recommendation. When real cannabis debt opportunities emerge, the group's forum and shared documentation provide the infrastructure for rigorous, collaborative evaluation.

Future outlook: how industry evolution could reshape cannabis credit

The medium-term trajectory for cannabis credit (2026–2032) hinges on several interrelated scenarios.

Incremental state-level legalization continues to expand the addressable market. New adult-use programs create lending opportunities in states where operators need capital for buildout - often at wider spreads than mature markets. Germany legalized recreational cannabis in April 2024, and other European nations are watching closely, potentially opening international markets for specialized lenders.

Federal rescheduling or descheduling remains the most consequential variable. If all cannabis moves to Schedule III - or is descheduled entirely - the elimination of 280E would dramatically improve operator cash flows, reduce credit risk, and attract mainstream banking capital. However, this also means spread compression: the very scarcity premium that makes cannabis debt attractive today would erode as competition increases.

Operator consolidation is likely as the industry matures. Larger multi-state operators will absorb smaller players, potentially improving credit quality but concentrating risk. Some specialized cannabis lenders may themselves be acquired by larger private credit platforms once regulatory risk declines sufficiently.

Evolving public health evidence on cannabis use disorder prevalence, cannabis withdrawal, secondhand cannabis, and cardiovascular risks could trigger either tighter or more permissive regulations. Non-combustible consumption methods - precision dosing, pharmaceutical-grade formulations, and medically focused products - are gaining share, potentially shifting revenue mix and collateral types away from cultivation real estate toward extraction technology and pharma-grade manufacturing.

Technological trends in the cannabis plant's cultivation and processing - including automated growing systems and AI-driven yield optimization - may alter the capital requirements and collateral profiles that lenders evaluate.

The most probable outcome: cannabis debt remains a niche, high-spread opportunity for the next 3–5 years, then gradually converges toward mainstream private credit as legal and societal acceptance broadens. Investors who enter now capture the premium; those who wait may find a more normalized - and less rewarding - landscape.

Build flexibility into your strategy. Today's opportunity set may look very different a decade from now.

Conclusion: key takeaways for accredited investors considering cannabis private debt

The structural capital gap in the cannabis industry creates a genuine income opportunity for accredited investors willing to navigate regulatory complexity. Senior secured cannabis debt offers contractual cash flows, hard-asset collateral, and double-digit yields that compensate for risks that traditional credit markets don't face.

Cannabis private debt holds clear advantages over cannabis equity for income-oriented investors: seniority in the capital stack, recourse to real estate and licenses, contractual coupon payments, and better downside protection when structured prudently. The boom-bust equity cycle of 2018–2021 underscored why debt investors in this sector have fared materially better.

The primary risks - regulatory uncertainty, enforcement complexity, 280E tax drag, and sector-specific operator fragility - cannot be diversified away entirely. High yields are compensation for these real uncertainties, not a free lunch.

Practical next steps:

1. Define your target allocation size (5–10% of private credit sleeve as a starting point)
2. Identify 2–3 candidate managers using the due diligence framework outlined above
3. Apply the checklist rigorously - especially around collateral enforceability and regulatory counsel
4. Leverage the 506 Investor Group's collective insights and negotiating power before committing capital
5. Monitor regulatory developments at least quarterly and rebalance as conditions evolve

Cannabis private debt can be a compelling specialist sleeve in a broader alternatives portfolio. It rewards investors who combine disciplined underwriting with regulatory awareness - and it punishes those who chase headline yields without understanding what lies beneath the structure.